This site is intended for health professionals only

Cancer drugs boost sales for Roche

teaser

Strong demand for Roche’s cancer medicines helped the drugs firm increase its third-quarter sales by 6%.

The Swiss-based firm revealed that sales reached £4.6bn for the period, up from £4.3bn for the third quarter last year.

Roche also reported a 12% increase in sales from January to September to £14.1bn, up from £12.6bn for the first nine months of last year.

The firm said the results had been helped by sales of the company’s cancer medicines and a positive market response to EU approval for its cancer drug Avastin® (bevacizumab) in August.

The drug has been approved by EU authorities to treat advanced non-small-cell lung cancer – the most common form of the disease – which kills more than 3,000 people a day worldwide.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Roche said sales of Avastin increased 41% during the first nine months of this year compared with the same period in 2006.

And sales of breast cancer treatment Herceptin® (trastuzumab) soared 26% between January and September, the company added.

Roche also revealed that it has now filled all of its government and corporate orders for Tamiflu® (oseltamivir), which many countries are stockpiling as part of plans to deal with any future influenza pandemic.

As a result, sales of the drug fell by more than £166m in the third quarter compared with the same period last year.

Copyright © PA Business 2007

Roche






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x